Padeliporfin treatment for non-removable pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent
- Have stage III pancreatic ductal adenocarcinoma confirmed on scans and/or tissue testing
- Have a tumor that surgery cannot remove (unresectable), specifically in the head or near the “uncinate” part of the pancreas
- No spread to other organs (metastatic disease) on a CT scan of chest/abdomen/pelvis within 28 days
- Be able to get the catheter safely: the tumor must touch an important nearby artery in a specific way, with adequate vessel size
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This trial tests a new treatment that uses ultrasound to help chemotherapy reach liver tumors in people with advanced pancreatic cancer. It may help shrink tumors and improve how well the chemotherapy works.
This trial tests a new treatment that uses light to activate a drug attached to cancer cells, aiming to destroy them during surgery. It is for people with pancreatic cancer that has not spread and who have already had chemotherapy.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
Hear when a new Locally Advanced Unresectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.